Prognosis
Two-Thirds of Severe Covid-19 Cases Improved on Gilead Drug
- Patients got experimental drug on a compassionate use basis
- Definitive evidence of safety will require clinical trials
This article is for subscribers only.
We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
Gilead Sciences Inc.’s experimental drug for patients with severe Covid-19 infections showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.